Novartis CEO: Company set to become a pure play, innovative medicine business after Sandoz spin off

Vas Narasimhan, CEO at Novartis, discusses the company's 100% spin off of Sandoz, its generic and biosimilar medicines business, and what the deal means for shareholders.